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by the –148C>T mutation, nor by any other putative
mutation linked to this change. The –148C>T mutation
in the erythroid-specific promoter of PKLR should, there-
fore, be considered a benign polymorphism. The basis for
the lowered PK activity in the 3 individuals presented
here thus remains to be established.
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Molecular studies reveal a concordant KEL
genotyping between patients with
hemoglobinopathies and blood donors 
in São Paulo City, Brazil 
Kell is the most important blood group system after
ABO and Rh because all frequently occurring Kell-specif-
ic antibodies must be considered clinically significant. The
highly immunogenic Kell antigens are usually involved in
red cell (RBC) alloimmunization that can cause either
hemolytic transfusion reactions or perinatal hemolytic
disease. Patients with hemoglobinopathies such as sickle
cell disease (SCD) require frequent blood transfusions.
Therefore, they often become alloimmunized and pro-
duce antibodies to low-prevalence Kell antigens, especial-
ly KEL1.1-4 The Kell low-prevalence antigens are
expressed due to single-nucleotide polymorphisms in the
KEL exons and some of them show ethnic or racial speci-
ficity. KEL1 is present in 9% of Caucasians and 2% of
those of African descent, KEL6 is expressed in 19.5% of
Africans and in less than 0.01% of white Caucasians,
while KEL3 is found in 2.3% in Caucasians and is rare
among Africans.1 The incidence of alloimmunization,
although multifactorial in etiology, is particularly high in
SCD patients when compared with other multitransfused
patients, primarily due to the disparity of phenotyping
pattern distribution which is partly caused by ethnic or
racial differences between the blood donor population
and the SCD patient population.2,4 Extended antigen-
matched RBC transfusion has been recommended for
reducing the incidence of alloimmunization in patients
with SCD. This practice adds greatly to the cost of provid-
ing blood components to these patients and can cause dif-
ficulties in finding RBC units for all patients.2,3 In order to
evaluate differences in KEL genotyping distribution
between blood donors and patients with SCD, and the
benefit of providing extended antigen-matched RBC
transfusion in multitransfused patients, we investigated
the frequencies of different KEL genotypes in patients
with hemoglobinopathies and blood donors in São Paulo
City, the largest city in Brazil. The Ethics Committee
Board approved the study.
Aliquots of EDTA-anticoagulant peripheral venous
blood were collected from 108 Brazilian patients of
African descent with hemoglobinopathies and 205 ran-
domized blood donors. Genomic DNA was isolated from
whole blood using a commercial kit (QIAamp DNA Blood
mini kit, Qiagen, Hilden, Germany). Employing poly-
merase chain reaction–restriction fragment length poly-
morphism (PCR-RFLP) technique, we performed the
KEL*1,2,  KEL*3,4,21 and KEL*6,7 genotyping as previous-
ly described.5-7 The differences between the KEL genotype
frequencies in the two groups were analyzed by Fischer’s
exact test. p values of 0.05 were considered statistically
significant. The results of the frequencies for KEL*1,2,
KEL*3,4,21 and KEL*6,7 polymorphisms are summarized
in Table 1. The KEL*1/2 genotype was found in 6.5%
(7/108) of patients with hemoglobinopathies and in 6.3%
(13/205) of blood donors. The KEL*3/4 genotype was
observed in only 1.0% (2/205) of blood donors. The
KEL*6/7 genotype was found in 6.5% (7/108) of patients
with hemoglobinopathies and in 4.4% (9/205) of blood
donors. We also found 1 (0.5%) donor with the KEL*6/6
genotype. No KEL*21 allele, KEL*1/1, or KEL*3/3 geno-
types were identified among the 313 subjects. There was
no statistically significant difference between the frequen-
cies of KEL*1/2, KEL*3/4 and KEL*6/7 genotypes seen in
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patients with hemoglobinopathies compared to those
observed in blood donors.
Patients with hemoglobinopathies commonly require
RBC transfusion to manage clinical complications such as
anemia, acute chest syndrome, stroke, and splenic seques-
tration. Overall, RBC alloimmunization in transfused
patients with SCD has a reported incidence of up to 40%.
Alloantibodies against Kell antigens, especially anti-KEL1,
have been observed as one of the most frequent antibod-
ies in multitransfused SCD patients. Anti-KEL1 alloimmu-
nization has a reported incidence of 28.1% up to 76.9%
among alloimmunized SCD patients in North America and
Europe,2-4,8,9 however, there are few data regarding the RBC
alloimmunization rate in South American SCD patients.
Table 2 summarizes the results of some studies evaluating
RBC alloimmunization in patients with hemoglo-
binopathies. We have reported an overall RBC alloimmu-
nization rate of 12.9% (11/85) in SCD Brazilian patients,
and anti-KEL1 specific alloimmunization rate of 18.2%
(2/11) among such subjects.10 A larger Brazilian study
described an overall RBC alloimmunization rate of 9.9%
(82/828) and anti-KEL1 specific alloimmunization frequen-
cy of 14.6% (12/82) among alloimmunized SCD patients,11
suggesting a lower KEL alloimmunization risk for patients
in Brazil.
A frequently recommended strategy for reducing the
incidence of RBC alloimmunization in patients with SCD
is to provide RBC transfusion matched for ABO, Rh (D),
and additional blood group antigens, ranging from limited
matching, i.e., C, E, and K antigens, to extended matching
for as many as 8 additional antigens, i.e., C, c, E, e, K, S,
Fya, Fyb, and Jkb.2,3 Besides the benefit of the phenotype
matching protocols that would prevent alloimmunization
in 52% to 70.8% of all immunized patients, these strate-
gies may also diminish the risk of delayed hemolytic trans-
fusion reactions, hyperhemolysis syndrome, and autoanti-
body formation. On the other hand, these protocols
demand high cost, need access to uncommon RBCs phe-
notypes, and do not totally avoid the risk of alloimmuniza-
tion, or the occurrence of delayed hemolytic transfusion
reactions or hyperhemolysis syndrome.2,3
Molecular techniques have been used in transfusion
medicine as an alternative tool to serological methods in
order to investigate patients who have been recently trans-
fused, or when antibody reagents, such as anti-Jsa and anti-
Jsb, are scarce or not commercially available.1 Using molec-
ular studies, we demonstrated that the frequency of the
KEL*1/2 (6.5%) and KEL*6/7 (6.5%) genotypes among
Brazilian patients with hemoglobinopathies differed from
those usually observed in subjects of African descent.
Moreover, the frequency of the KEL*1/2 (6.3%) and
KEL*6/7 (4.4%) genotypes in blood donors differed from
those to be expected in a Caucasian population or in sub-
jects of African descent, but quite similar to the results
observed in our patients with hemoglobinopathies. These
findings suggest a high rate of racial admixture in Brazilian
patients of African descent with hemoglobinopathies, as
well as in Brazilian blood donors, and possibly explain the
lower risk of Kell alloimmunization seen in Brazilian SCD
patients.10,11
In conclusion, the observed concordant KEL genotyping
donor-recipient population suggests that Brazilian patients
are at a lower risk of Kell alloimmunization than that
reported in studies from North America and Europe where
the donor population is predominantly formed by white
Caucasians. In addition, our data indicate that the require-
ment for extended antigen-matched RBC transfusion in
multitransfused patients may not be cost-effective in
Brazil.
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Table 2. Results of studies reporting RBC alloimmunization rate
and anti-KEL1 specific alloimmunization frequency among alloim-
munized SCD patients.




Rosse et al.8 USA 1,814 18.6% (338/1,814) 28.1% (95/338)
Vichinsky et al.4 USA 107 29.9% (32/107) 56.2% (18/32)
Moreira et al.10 Brazil 85 12.9% (11/85) 18.2% (2/11)
Aygun et al.2 USA 140 37.1% (52/140) 76.9% (40*/52)
Castro et al.3 USA 351 39% (137/351) 38% (52/137)
Murao and Viana11 Brazil 828 9.9% (82/828) 14.6% (12/82)
Schonewille et al.9 Netherlands 1,778† NR 30% (541/1778)
n: number of transfused patients; *Included anti-KEL7 (anti-Jsb);
†Alloimmunized patients (not only SCD); NR: not reported.
Table 1. Frequencies of KEL*1,2, KEL*3,4,21 and KEL*6,7 genotypes of patients with hemoglobinopathies and blood donors in Brazil.
Group (n) KEL*1/2 KEL*2/2 KEL*3/4 KEL*4/4 KEL*6/6 KEL*6/7 KEL*7/7 
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Hemoglobinopathies† (108) 7 (6.5) 101 (93.5) 0 108 (100) 0 7 (6.5) 101 (93.5)
Blood donors (205) 13 (6.3) 192 (93.7) 2 (1.0) 203 (99.0) 1 (0.5) 9 (4.4) 195 (95.1)
p value > 0.999 0.547 0.430
†HbSS:n= 79; HbSC:n=19; HbS-Thal:n= 6; HbCC:n= 4 
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Association of asymmetric dimethylarginine with
sickle cell disease-related pulmonary hypertension
Pulmonary hypertension (PHT) occurs in approximate-
ly 30% of adult sickle cell patients and is associated with
a high risk of early death. Hemolysis driven reductions in
nitric oxide (NO) bioavailability resulting from NO scav-
enging by cell free hemoglobin and increased arginase
activity are of importance in the pathophysiology of SCD
related PHT.1
Elevated plasma concentrations of asymmetric
dimethylarginine (ADMA) contribute to limiting NO
bioavailability in SCD.2 ADMA and symmetric dimethy-
larginine (SDMA) derive from the irreversible post-trans-
lational methylation of arginine residues by protein argi-
nine methyltransferases (PRMT) and are released as free
amino acids upon proteolysis. ADMA (but not SDMA)
competitively inhibits NO synthase (NOS) enzymes,
thereby limiting NO production. ADMA is degraded by
dimethylarginine dimethylaminohydrolases (DDAH)
whereas SDMA is mainly cleared renally.3 Elevated plas-
ma ADMA concentrations occur in several forms of PHT
and are associated to PHT outcome.4,5 We investigated
whether ADMA concentrations are associated with PHT
in SCD. 
Serum and EDTA plasma samples were available from
adult sickle cell patients consecutively screened for PHT
with echocardiography as previously reported.6 Mild and
moderate-severe PHT are defined as tricuspid regurgitant
jet flow velocity (TRV) of 2.5-2.9 m/s and TRV≥3 m/s
respectively, with pulmonary-artery pressures considered
normal in patients with trace or no tricuspid regurgita-
tion (with TRV assigned 1.3 m/s).1 Plasma concentrations
of ADMA, SDMA, amino acids and serum soluble vascu-
lar cell adhesion molecule-1 (sVCAM-1) levels were
determined as previously described.2,7 For analysis, HbSS
and HbSβ0-thalassemia patients were grouped together,
as were HbSβ+-thalassemia and HbSC patients. p-values
<0.05 were considered statistically significant (SPSS
12.0.2, SPSS Inc, Chicago, IL, USA). The study was carried
out in accordance with the principles of the Declaration
of Helsinki.
Two out of 19 PHT patients had moderate-severe PHT.
Hydroxyurea use did not differ between patients with
and without PHT and no patients used anticoagulation,
calcium antagonists, endothelin receptor blockers or
sildenafil. Between group comparisons were only per-
Table 1. Demographics and laboratory parameters in sickle cell
patients with and without pulmonary hypertension. 
HbSS (n=40)/ HbSC (n=16) / 
HbSβ0-thalassemia (n=6) HbSβ+-thalassemia (n=5) 
PHT– PHT+ p PHT– PHT+
N 28 18 20 1
Age (years) 33 (21-44) 28 (22-52) 0.80 29 (23-39) 41
Male:female 6:22 5:13 10:10 0:1
TRV (m/s) 2.0 (1.3-2.3) 2.7 (2.6-2.8) 2.1 (1.3-2.2) 2.6
sPAP*(mmHg) 21 (12-28) 34 (32-43) 21 (12-25) 31
Hb (mmol/L) 5.7 (5.0-6.2) 4.9 (4.2-5.9) 0.05 7.0 (6.6-7.6) 6.5
HbF (%) 10.6 5.9 0.13 1.0 4
(6.1-18.3) (2.2-14.1) (1.0-2.4)
LDH (U/L) 369 575 0.02 231 261
(300-515) (388-846) (202-359)
GFR (mL/min)** 151 120 0.10 140 114
(120-195) (66-172) (125-160)
ADMA (µmol/L) 0.57 0.63 0.01 0.50 0.48
(0.52-0.65) (0.58-0.79) (0.45-0.58)
SDMA (µmol/L) 0.47 0.51 0.07 0.46 0.47
(0.42-0.55) (0.47-0.83) (0.44-0.56)
Arginine (µmol/L) 45 46 0.26 67 56
(32-56) (41-62) (57-79)
Ornithine (mmol/L) 56 56 0.41 56 44
(42-66) (45-75) (49-62)
Citrulline (mmol/L) 23 27 0.66 29 32
(16-32) (20-32) (24-33)
Proline (mmol/L) 208 209 0.84 197 257
(162-257) (176-234) (148-247)
Arginine/ornithine 0.84 0.93 0.45 1.14 1.1
(0.66-1.0) (0.72-1.15) (0.86-1.21)
Arginine/citrulline 1.87 1.98 0.84 2.1 1.5
(1.66-2.49) (1.43-2.65) (1.6-2.3)
Arginine/proline 0.23 0.25 0.41 0.30 0.19
(0.18-0.31) (0.19-0.35) (0.21-0.37)
sVCAM-1 (ng/mL) 1089 1542 0.007 851 971
(801-1239) (1119-1880) (628-1011)
Data are presented as medians with their corresponding inter quartile range.
A p-value <0.05 is considered statistically significant. *Right ventricular systolic
pressure was estimated based on the modified Bernoulli equation (1) and
considered to be equal to the systolic pulmonary artery pressure (sPAP) in
absence of right ventricular outflow obstruction. **Glomerular filtration (GFR)
rate calculated with Cockcroft and Gault-formula (males: creatinine clearance=
1.23xweight x (140-age)/serum creatinine, females: creatinine clearance =
1.03xweight x (140-age)/serum creatinine). 
